Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 2 Oct - Copy of newspaper advertisements for Transfer and Dematerialisation of Physical Securities.
Source: Bse
Pfizer Limited (PFIZER)
Large CapPharma stocks · Large cap · NSE
Pfizer Limited operates in Formulations, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
Data qualityFresh enough for analysisQuote updated 21 Oct, 03:31 pm ISTDetails
Quote21 Oct, 03:31 pm IST
Base fundamentals15 Oct 2026 · screener
Latest result16 Aug, 12:36 am IST
Score22 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags02 May 2026
Coverage13/14 · 93%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens
Trend score and candlestick chart
53Neutralfull bear SMA stack · SMA20 -12.1% / mo · MACD + · near 52W low · sector +4.9pp vs Nifty 500 (3M)
Stock trend: 24
Sector RS: 97
Sector 3M: -0.3% vs Nifty 500 -5.2%
Pharma FPI tailwindNot confirmed
Latest mapped FPI equity flow was not positive. View sector evidence
Technical chart
PFIZERD candles · FIT view-21.6%Latest close ₹3754.70 on 2026-10-21
Bar
-1.4%
RSI
33
MACD hist
17.55
52W pos
1%
2026-10-21O ₹3808.70H ₹3808.70L ₹3740.00C ₹3754.70Vol 12,027 sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
PFIZERNifty PharmaNifty 500
- PFIZER
- -18.3%
- Nifty 500
- -6.5%
- Nifty Pharma
- -2.0%
- Vs Nifty 500
- -11.8 pp
Chart stats
21 Oct 2026- From 52W high
- -32.7%
- 52W range position
- 1%
- ATR (14)
- 2.7%
- Volume vs 20D
- 0.33x
- Avg traded value
- ₹14 Cr
- 20D price channel
- ₹3,731 - ₹4,123.9
₹5,578.5
₹3,731 - ₹5,578.5
₹100.4
Latest completed session
20-session average
27.1% annualized volatility
Research snapshot
What the evidence says now
Weak fundamentals, management evidence is still limited to a financial-only Trust Lite signal, price trend is neutral, and recent execution is mixed.
Suggested next step
Research, do not rush
The evidence is not strongly aligned. Compare peers and wait for a cleaner setup.
U-Score
Legacy · WATCHLIST33
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Average45
Revenue +8.3% · PAT +6.3% YoY
Technical
Neutral53
Price trend and sector-relative-strength timing.
Valuation
Legacy model-725.6%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence78
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 30 Jun 2026
Average · 45/100Rev +8% YoY · PAT +6% YoY · margin expansion
Filed 30 Jun 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹653 Cr | +8.3% | +3.8% |
| EBITDA | ₹248 Cr | +18.1% | +5.1% |
| Operating margin | 38.0% | +300 bps | +0 bps |
| PAT | ₹204 Cr | +6.3% | +2.0% |
| PAT margin | 31.2% | -60 bps | -56 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 117.00
- P/B
- 13.00
- EV/EBITDA
- —
- Market Cap
- 17956.00Cr
Profitability
- ROE
- 19.80%
- ROCE
- 27.20%
- ROA
- 27.32%
- Dividend Y
- 1.91%
Growth (CAGR)
- Revenue 5Y
- -7.00%
- EPS 5Y
- -7.00%
- Revenue 3Y
- -7.00%
- EPS 3Y
- -7.00%
Balance Sheet
- Debt/Equity
- 0.00
- Interest Coverage
- —
- Altman Z
- 7.78
- Book Value
- 302.00
Cash Flow
- FCF Yield
- 0.89%
- FCF Positive Y
- 3/5
- OCF
- 238.00 Cr
- EPS TTM
- 100.39
Shareholding
- Promoter Hold
- 63.92%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 11%
Financial History
Updated 22/10/2026
Revenue
₹ CrLatest: 653+3.8% vs prev
Net Profit
₹ CrLatest: 204+2.0% vs prev
ROE is shown only in the Annual view — quarterly equity data isn't published.
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Bearish setupTrend is weak — long-term trend down. RSI 33.
- Price < SMA20 < SMA50 < SMA200 — full bearish stack.
- SMA20 falling (~13.7% over last month) — short-term momentum negative.
- RSI(14) at 33 — falling, no extreme reading.
- MACD above signal but histogram contracting — bullish momentum cooling.
- Within 5% of 52-week low — testing support.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
15
RS percentile
Stage 4 Downtrend
1M return
-7.0%
3M return
-18.3%
6M return
-21.5%
1Y return
-28.7%
RS 1D
0
RS 20D
+1
Sector rank
#2
Industry rank
#3
Stage evidence
- Price is 17.6% below the 30-week proxy.
- The 50-DMA is below the 30-week proxy and its slope is falling -2.8%.
- Both 3-month and 6-month returns are negative.
50-DMA
price below
200-DMA
price below
Sector
leading
Industry
leading
Relative-strength line vs Nifty 500 (base 100)
262 observations
21 Oct 2026Value 79.7-0.50%
RS vs Nifty 50080
Valuation & peers
U-Score 33 · legacy U-Score band WATCHLIST · valuation evidence and comparable companies
Valuation & peers
U-Score 33 · legacy U-Score band WATCHLIST · valuation evidence and comparable companies
WATCHLIST
Fundamental score breakdown
U band · WATCHLISTValuation0/30
Growth2/25
Quality14/20
Balance Sheet10/15
Cash Flow3/10
Piotroski
6/9 (+3)
Penalties
1
Raw sum
33
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
33/100 · legacy band WATCHLIST
Positive drivers
- Quality contributes 14/20 to the score.
- Balance sheet contributes 10/15 to the score.
- Cash flow contributes 3/10 to the score.
Main drags
- Fair-value margin of safety is negative at -725.6%.
- Valuation is weaker at 0/30; verify the latest quarterly trend.
- Growth is weaker at 2/25; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
117.0
PB
13.0
EV/EBITDA
—
ROE
19.8%
ROCE
27.2%
FCF Yield
0.9%
Debt/Equity
0.0
MoS
-725.6%
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 22 Oct 2026
v4.3-runtime-valuation
Final score
33
Previous: 33
Legacy U-Score band
WATCHLIST
Previous: WATCHLIST
Margin of safety
-725.6%
Previous: -725.6%
Score history
12 stored score snapshots. Latest stored move: +0 points.
22 Oct 2026
v4.3-runtime-valuation
33
33
33
33
33
33
33
33
33
33
33
33
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
₹825.92
-354.6% MoS
Growth-justified P/E
4.5
Growth-justified Value
₹454.77
-725.6% MoS
PEG
—
Comparable companies
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
ALIVUS
Large
Alivus Life Sciences Limited
Pharmaceuticals
match 166
29
43.7
—
+14%
OVERVALUED
CAPLIPOINT
Large
Caplin Point Laboratories Limited
Pharmaceuticals
match 165
61
26.3
20.9%
+44%
UNDERVALUED
ERIS
Large
Eris Lifesciences Limited
Pharmaceuticals
match 165
55
24.5
18.7%
+46%
FAIR VALUE
APLLTD
Mid
Alembic Pharmaceuticals Limited
Pharmaceuticals
match 161
34
20.8
13.4%
-453%
WATCHLIST
ASTRAZEN
Small
AstraZeneca Pharma India Limited
Pharmaceuticals
match 159
43
85.2
23.3%
-99%
WATCHLIST
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Issuer presentation review pending
Pfizer Limited operates in Formulations, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 30 Jun 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trust Score
78Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 86th percentile of the scored universe and 78th percentile within Pharma. No major sub-score weakness stands out.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 22 Oct 2026
management-trust-v1
20 docs text-extracted · 9 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
86th percentile
overall median 67 · Pharma: 78th pctile, median 70 · Large: 70th pctile, median 73
Evidence depth
Financial-only
20 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Can support position sizing if valuation and trend also agree.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
86
strong · holding, pledge, alignment
Cash flow
65
acceptable · profit to cash conversion
Balance sheet
88
strong · leverage and solvency
Discipline
82
strong · capital discipline
Results
72
acceptable · quarterly consistency
Trust positives
- ▸Promoter holding is 63.9%.
- ▸Promoter pledge is zero.
- ▸FCF yield is positive at 0.9%.
- ▸Debt/equity is 0.00.
Trust risks
- ▸1 of the latest 4 quarters had PAT decline worse than 25% YoY.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Pfizer Limited
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
AnnouncementSep 2026
Sep 2026 · Announcement under Regulation 30 (LODR)-Change in Management 18 Sep - Sharad Goswami resigns as Senior Director, Policy & Public Affairs, effective September 25, 2026.
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 4 Aug - Newspaper Advertisement - Special Window for Re- lodgement of Transfer and Dematerialisation of Physical Securities.
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 7 Jul - Newspaper Advertisement - Notice of the 75th Annual General Meeting
Source: Bse
Annual reportMar 2026
Mar 2026 · Annual Report 2026
Source: Bse
Annual reportMar 2026
Jul 2026 · Letter To Shareholders Providing The Weblink To Access The Annual Report For Financial Year 2025-26. 7 Jul - Pfizer posts FY26 annual report link; 75th AGM on July 28, 2026; final dividend Rs.75 per share.
Source: Bse
Annual reportMar 2026
Jul 2026 · Reg. 34 (1) Annual Report. 6 Jul - Pfizer's 75th AGM on July 28, 2026; final dividend of ₹75 per share for FY26.
Source: Bse
Annual reportMar 2025
Mar 2025 · Annual Report 2025
Source: Bse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.